CN111374935A - 含多肽的组合物及其应用 - Google Patents
含多肽的组合物及其应用 Download PDFInfo
- Publication number
- CN111374935A CN111374935A CN202010249226.0A CN202010249226A CN111374935A CN 111374935 A CN111374935 A CN 111374935A CN 202010249226 A CN202010249226 A CN 202010249226A CN 111374935 A CN111374935 A CN 111374935A
- Authority
- CN
- China
- Prior art keywords
- extract
- fermentation product
- whitening
- product
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 229920001184 polypeptide Polymers 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 7
- 238000000855 fermentation Methods 0.000 claims abstract description 72
- 230000004151 fermentation Effects 0.000 claims abstract description 72
- 230000002087 whitening effect Effects 0.000 claims abstract description 61
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 36
- 208000026935 allergic disease Diseases 0.000 claims abstract description 36
- 230000007815 allergy Effects 0.000 claims abstract description 17
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims abstract description 16
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 13
- 239000003906 humectant Substances 0.000 claims abstract description 12
- GFEYWOGCSROPRT-OBXVVNIGSA-N (2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 GFEYWOGCSROPRT-OBXVVNIGSA-N 0.000 claims abstract description 7
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 claims abstract description 7
- 239000011159 matrix material Substances 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims description 106
- 239000000284 extract Substances 0.000 claims description 79
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 23
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 23
- 239000002562 thickening agent Substances 0.000 claims description 22
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 16
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 16
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 15
- -1 polydimethylsiloxane Polymers 0.000 claims description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 13
- 229960000458 allantoin Drugs 0.000 claims description 13
- 239000011570 nicotinamide Substances 0.000 claims description 12
- 229960003966 nicotinamide Drugs 0.000 claims description 12
- 235000005152 nicotinamide Nutrition 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 11
- 239000006166 lysate Substances 0.000 claims description 11
- 244000269722 Thea sinensis Species 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 9
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 8
- 241000218378 Magnolia Species 0.000 claims description 8
- 240000002853 Nelumbo nucifera Species 0.000 claims description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 8
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229960005150 glycerol Drugs 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229940064064 purslane extract Drugs 0.000 claims description 6
- 241000167550 Centella Species 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 4
- 244000042664 Matricaria chamomilla Species 0.000 claims description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 4
- 241000235346 Schizosaccharomyces Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000002489 tectorial membrane Anatomy 0.000 claims description 4
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 240000001341 Reynoutria japonica Species 0.000 claims description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 3
- 241000235342 Saccharomycetes Species 0.000 claims description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 229940048053 acrylate Drugs 0.000 claims description 3
- 229940059958 centella asiatica extract Drugs 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920006037 cross link polymer Polymers 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 229940047670 sodium acrylate Drugs 0.000 claims description 3
- 229950004959 sorbitan oleate Drugs 0.000 claims description 3
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 229940008099 dimethicone Drugs 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 229940092665 tea leaf extract Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 102000003425 Tyrosinase Human genes 0.000 abstract description 21
- 108060008724 Tyrosinase Proteins 0.000 abstract description 21
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 31
- 239000000686 essence Substances 0.000 description 27
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 241000628997 Flos Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009417 prefabrication Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
本发明涉及化妆品技术领域,尤其涉及含多肽的组合物及其应用。本发明提供组合物包括:保湿剂、烟酰胺、舒敏组分,九肽‑1,六肽‑11,美白发酵产物组分。该在适宜的配比下组合物具有良好的抗氧化效果、抑制酪氨酸酶活性的效果,且具有良好的舒敏效果,并且,精华液中的基质成分也有利于组合物效果的发挥,整体配方非常温和不具有刺激性,扩大了该精华液的适用范围。
Description
技术领域
本发明涉及化妆品技术领域,尤其涉及含多肽的组合物及其应用。
背景技术
从古至今,白皙、靓丽的皮肤一直是东方女性追求的。“爱美之心,人皆有之”,中国人每年在化妆品消费市场上的消费金额高达数千亿元。随着科学技术的发展以及对美白诉求的加强,科学家对美白的原理及美白产品的研究也在一步步加深。大量研究发现,黑色素的含量及分布决定着皮肤的颜色,美白机理即黑色素的抑制机理,主要包括抑制黑色素合成酶、抑制黑素细胞增殖、还原黑色素形成过程中各中间体或阻碍其结合、抑制黑色素转移和清除自由基来达到美白的效果。
如今,市面上存在各种各样的美白产品,大多数美白产品都是采用熊果苷、氢醌、凝血酸、维C乙基醚等化学成分抑制酪氨酸酶,从而实现美白的效果。但这类产品存在低剂量效果不理想乃至无效,高剂量不耐受问题,安全性差,致敏风险较大,而且也可能因使用过程暴露在光中而造成光照逆化导致皮肤黑色素增多,导致肤色更黑甚至长色斑等结果。因此,本领域存在“美白成分容易引起皮肤过敏”和“美白化妆品含有对身体有害成分”等观点,这些观点让很多消费者对美白化妆品望而却步。因此,目前本领域仍在进一步的研究温和的具有美白功效的化妆品。
发明内容
有鉴于此,本发明要解决的技术问题在于提供含多肽的组合物及其应用。本发明的组合物不仅具有清除自由基、抑制酪氨酸酶活性的活性,还具有舒敏的作用。
本发明提供的组合物包括:保湿剂、烟酰胺、舒敏组分,九肽-1,六肽-11、美白发酵产物组分,
所述保湿剂包括丁二醇、甘油、透明质酸钠和尿囊素;
所述美白发酵产物组分包括二裂酵母发酵产物溶胞物、酵母发酵产物提取物、覆膜酵母菌发酵产物滤液和乳酸杆菌发酵产物;
所述的舒敏组分包括积雪草提取物、虎杖根提取物、黄芩根提取物、马齿苋提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、玉兰花提取物和雪莲花提取物。
本发明中,所述保湿剂中丁二醇、甘油、透明质酸钠和尿囊素的质量比为:(3~7)∶(4~8)∶(0.03~0.1)∶(0.1~0.4)。本发明中,所述丁二醇为1,3-丁二醇,所述透明质酸钠为135万道尔顿分子量的透明质酸钠。一些实施例中,所述丁二醇、甘油、透明质酸钠和尿囊素的质量比为3∶8∶0.1∶0.1。另一些实施例中,所述丁二醇、甘油、透明质酸钠和尿囊素的质量比为7∶4∶0.03∶0.4。另一些实施例中,所述丁二醇、甘油、透明质酸钠和尿囊素的质量比为5∶4∶0.05∶0.2。
本发明中,所述美白组合物由二裂酵母发酵产物溶胞物、酵母发酵产物提取物、覆膜酵母菌发酵产物滤液和乳酸杆菌发酵产物组成,其中,二裂酵母发酵产物溶胞物会产生包括维他命B群、矿物质、氨基酸等有益护肤的小分子,不仅可以加强角质层的代谢,还能捕获自由基,抑制脂质的过氧化,起到美白和抗衰等功效;酵母发酵产物提取物能够抵抗皮肤衰老,对皮肤细胞活性再生和胶原蛋白质的合成具有良好的促进作用,同时,能够舒缓受损皮肤,有益皮肤的健康;覆膜酵母菌发酵产物滤液为制作清酒的酵母菌代谢物,组成物质包含氨基酸、矿物元素等,能够抑制自由基,改善肤质;乳酸杆菌发酵产物含有多肽、氨基酸和天然保湿因子等,不仅能够抗氧化,还能令肌肤表面形成屏障,达到抗衰老及抗炎的功效。所述美白发酵产物组分中,二裂酵母发酵产物溶胞物、酵母发酵产物提取物、覆膜酵母菌发酵产物滤液和乳酸杆菌发酵产物的质量比为5∶1∶2∶2。
所述舒敏植物组合物由积雪草提取物、虎杖根提取物、黄芩根提取物、马齿苋提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、玉兰花提取物、雪莲花提取物组成,积雪草提取物能改善痤疮性皮肤,防止色素沉淀,促进皮肤的胶原蛋白生成、改善皮肤弹性,延缓肌肤老化,紫外线照射后的晒后修复都被证实有显著效果;虎杖根提取物含有大黄和白藜芦醇等,具有美白、抑菌、抗皱、抗炎等功效;黄芩根提取物为淡黄色至棕黄色的粉末,具有抑菌、抗炎、抗过敏、抗氧化作用;马齿苋提取物具有抗过敏、止痒以及抑制皮肤红肿、抗自由基以及防止皮肤氧化以及消除皮肤炎症等功效;茶叶提取物富含茶多酚,具有强的保湿和舒缓肌肤的功效;光果甘草根提取物具有抗菌消炎、抗氧化、抗衰老、防紫外线、防晒、美白亮肤、祛斑等功效;母菊花提取物能够很好地舒缓皮肤,抵抗肌肤敏感,有抗炎、抗菌、抗氧化的作用;迷迭香叶提取物具有保护皮肤、活血、强化皮肤、促进皮肤机能等作用;玉兰花提取物对皮肤瘙痒、疱疮、肿毒能起到明显的改善作用,同时还具有光洁、美白肌肤的作用;雪莲花提取物主要作用是消炎、镇静、防衰老。所述舒敏组分中,积雪草提取物、虎杖根提取物、黄芩根提取物、马齿苋提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、玉兰花提取物、雪莲花提取物的质量比为1∶1∶1∶1∶1∶1∶1∶1∶1∶1。
本发明组合物中,烟酰胺主要通过抑制黑色素沉着,减少已经生成、沉淀的黑色素,阻隔黑色素向表层细胞的转移,加速细胞新陈代谢及加快黑色素角质细胞的脱落等来达到美白效果。而九肽-1,主要通过抑制MSH(促黑激素),减少黑色素生成,阻止黑色素过度产生等来达到美白效果。
本发明将具有舒敏效果的植物组合物与具有强美白功效的烟酰胺、美白发酵产物组合物和九肽-1组合,结合六肽-11的减少皮肤胶原蛋白和弹性蛋白流失的功效,使各组分相互协调产生明显的协同增效作用,从而使组合物在具有美白功效的同时,还具有舒敏的作用,且效果优于缺少某些组分的组合。
所述保湿剂、烟酰胺、舒敏组分,九肽-1,六肽-11,美白发酵产物组分的质量比为(7.13~15.5)∶(1~3)∶(0.2~1)∶(0.03~0.1)∶(0.01~0.05)∶(4~10)。一些实施例中,保湿剂、烟酰胺、舒敏组分,九肽-1,美白发酵产物组分的质量比为10.2∶1∶1∶0.03∶0.01∶10。另一些实施例中,保湿剂、烟酰胺、舒敏组分,九肽-1,美白发酵产物组分的质量比为11.43∶3∶0.2∶0.1∶0.02∶4。另一些实施例中,保湿剂、烟酰胺、舒敏组分,九肽-1,美白发酵产物组分的质量比为9.25∶2∶0.5∶0.05∶0.05∶7。
本发明所述的组合物在制备具有舒敏和/或美白功能的产品中的应用。
本发明还提供了一种具有舒敏和/或美白功能的精华液,其包括本发明所述的组合物和基质。
所述精华液中,本发明所述的组合物的质量分数为18.35%~23.24%。
所述精华液中,基质由双-PEG-15甲基醚聚二甲基硅氧烷、增稠剂、乳化增稠剂、黄原胶、对羟基苯乙酮、1,2-己二醇、PEG-40氢化蓖麻油、香精、三乙醇胺和水;
其中,所述增稠剂为丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物;
所述乳化增稠剂由丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷、聚山梨醇酯-80、水、山梨坦油酸酯组成。
本发明所述的精华液,其由如下质量分数的组分组成:
余量为水。
本发明所述精华液的制备方法,包括:
将透明质酸钠和黄原胶与丁二醇混合,记为预制品1;
将香精加入PEG-40氢化蓖麻油,记为预制品2;
将对羟基苯乙酮加入丁二醇,升温至60~70℃,搅拌溶解,记为预制品3;
将三乙醇胺与水混合,记为预制品4;
将烟酰胺溶于水,记为预制品5;
取剩余的水,将增稠剂缓慢撒水面上,浸泡5~8min后30~35Hz,搅拌2~4min,再加入甘油、剩余的丁二醇、尿囊素、预制品1,升温至85~90℃,保温搅拌15~20min后,加入双-PEG-15甲基醚聚二甲基硅氧烷、乳化增稠剂,真空度-0.04~-0.08MPa,3000r/min均质15min,然后35~40Hz搅拌;
降温至45~50℃,加入舒敏组分、1,2-己二醇、美白发酵产物组分、预制品2、预制品3、预制品4、预制品5,保持真空-0.04~-0.08MPa,搅拌10~15min,降温至室温,制得所述精华液。
本发明提供组合物包括:保湿剂、烟酰胺、舒敏组分,九肽-1,美白发酵产物组分。该在适宜的配比下组合物具有良好的抗氧化效果、抑制酪氨酸酶活性的效果,且具有良好的舒敏效果,并且,精华液中的基质成分也有利于组合物效果的发挥,整体配方非常温和不具有刺激性,扩大了该精华液的适用范围。
具体实施方式
本发明提供了含多肽的组合物及其应用,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明采用的试材皆为普通市售品,皆可于市场购得。其中:
所述二裂酵母发酵产物溶胞物(BIFIDA FERMENT LYSATE)、酵母发酵产物提取物(YEAST FERMENT EXTRACT)、覆膜酵母菌发酵产物滤液(SACCHAROMYCOPSIS FERMENTFILTRATE)、乳酸杆菌发酵产物(LACTOBACILLUS FERMENT)均为市售。
所述九肽-1由水、甘油、九肽-1复配所得,为市售产品;
所述六肽-11由水、甘油、六肽-11复配所得,为市售产品;
积雪草提取物,主要成分为积雪草苷,通过对积雪草进行粉碎过筛、超声辅助醇提、过滤浓缩、脱色、除醇、纯化等进行提取。
虎杖根提取物,主要成分为含白藜芦醇和大黄素等,通过对虎杖根进行粉碎过筛、石油醚浸提、除石油醚、超声辅助醇提、过滤浓缩、脱色、除醇、纯化等进行提取。
黄芩根提取物,主要成分为黄芩苷、黄芩素等黄酮类化合物,通过对黄芩进行粉碎过筛、超声水提、一定温度下保温一定时间进行沉淀、过滤、水洗、干燥等进行提取。
马齿苋提取物,主要成分为植物多糖和维生素,通过对马齿苋进行水和水解酶酶解提取、醇提、过滤、浓缩等进行提取。
茶叶提取物,富含茶多酚,通过对茶叶进行粉碎、水提、醇提、酶解、超滤、浓缩、干燥等进行提取。
光果甘草根提取物,主要成分为甘草黄酮、甘草皂苷和甘草多糖等,通过对光果甘草根进行粉碎过筛、超声辅助醇提、过滤浓缩、纯化等进行提取。
母菊花提取物,主要成分为黄酮类化合物、氨基酸、绿原酸等,通过对母菊花进行粉碎过筛、超声辅助醇提、过滤浓缩、纯化等进行提取。
迷迭香叶提取物,主要成分为萜酚类等,通过对迷迭香叶进行粉碎过筛、超声辅助醇提、过滤浓缩、纯化等进行提取。
玉兰花提取物,主要成分为黄酮类化合物,通过对玉兰花进行粉碎过筛、超声水提、一定温度下保温一定时间进行沉淀、过滤、水洗、干燥等进行提取。
雪莲花提取物,主要成分为黄酮类、多糖等,通过对雪莲花进行超声辅助醇提、过滤浓缩、纯化等进行提取。
在一些具体实施例中,本发明所述的具有舒敏和/或美白功能的精华液,每100g由下述质量数的组分制成:丁二醇3g,甘油8g,烟酰胺1g,透明质酸钠0.1g,尿囊素0.1g,舒敏植物组合物1g,九肽-10.03g,六肽-110.01g,美白发酵产物组合物10g,双-PEG-15甲基醚聚二甲基硅氧烷1g,增稠剂0.1g,乳化增稠剂0.7g,黄原胶0.02g,对羟基苯乙酮0.7g,1,2-己二醇0.2g,PEG-40氢化蓖麻油0.05g,香精0.01g,三乙醇胺0.1g,余量为水。
在一些具体实施例中,本发明所述的具有舒敏和/或美白功能的精华液,每100g由下述质量数的组分制成:丁二醇7g,甘油4g,烟酰胺3g,透明质酸钠0.03g,尿囊素0.4g,舒敏植物组合物0.2g,九肽-10.1g,六肽-110.02g,美白发酵产物组合物4g,双-PEG-15甲基醚聚二甲基硅氧烷3g,增稠剂0.3g,乳化增稠剂0.2g,黄原胶0.1g,对羟基苯乙酮0.2g,1,2-己二醇0.7g,PEG-40氢化蓖麻油0.2g,香精0.05g,三乙醇胺0.3g,余量为水。
在一些具体实施例中,本发明所述的具有舒敏和/或美白功能的精华液,每100g由下述质量数的组分制成:丁二醇5g,甘油4g,烟酰胺2g,透明质酸钠0.05g,尿囊素0.2g,舒敏植物组合物0.5g,九肽-10.05g,六肽-110.05g,美白发酵产物组合物7g,双-PEG-15甲基醚聚二甲基硅氧烷1.5g,增稠剂0.15g,乳化增稠剂0.35g,黄原胶0.05g,对羟基苯乙酮0.5g,1,2-己二醇0.5g,PEG-40氢化蓖麻油0.2g,香精0.05g,三乙醇胺0.15g,余量为水。
上述3个组方在本发明中被依次记为组1~3,而在本发明中,为了证明本发明的提供精华液的效果,将上述本发明所制备得到的精华液组1~3进行功效验证,同时设置组4~9为阳性对照样品。取组1~9的样品进行DPPH自由基清除率、ABTS自由基清除率、酪氨酸酶活性抑制率测试、并进行消费者舒敏效果评价,其中:
组4:其它组分与组3一样,不同之处在于用7g烟酰胺取代7g美白发酵产物组合物。
组5:其它组分与组3一样,不同之处在于用2g美白发酵产物组合物取代2g烟酰胺。
组6:其它组分与组3一样,不同之处在于用0.05g美白发酵产物组合物取代0.05g九肽-1。
组7:其它组分与组3一样,不同之处在于用2g美白发酵产物组合物取代2g。
组8:其它组分与组3一样,不同之处在于美白发酵产物组合物只含二裂酵母发酵产物溶胞物、酵母发酵产物提取物和乳酸杆菌发酵产物。
组9:其它组分与组3一样,不同之处在于不含舒敏植物组合物。
下面结合实施例,进一步阐述本发明:
实施例1
二裂酵母发酵产物溶胞物5质量份、酵母发酵产物提取物1质量份、覆膜酵母菌发酵产物滤液2质量份和乳酸杆菌发酵产物2质量份,混合制得美白发酵产物组分。
实施例2
积雪草提取物、虎杖根提取物、黄芩根提取物、马齿苋提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、玉兰花提取物、雪莲花提取物等质量比混合,制得舒敏组分。
对比例1
二裂酵母发酵产物溶胞物5质量份、酵母发酵产物提取物1质量份和乳酸杆菌发酵产物2质量份,混合制得美白发酵产物组分。
实施例3
按照表1配方制备精华液:
表1精华液配方(每100g含有)
注:表中增稠剂为丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物;
表中乳化增稠剂由丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷、聚山梨醇酯-80、水、山梨坦油酸酯组成,各组分的质量比为(35~40)∶(20-25)∶(5~10)∶(22.5~37.5)∶(0~5)。
表中所述舒敏组分来自实施例2。
制备方法为:
1)按比例称取各个组分;
2)将透明质酸钠和黄原胶用一定量的丁二醇搅拌分散均匀,记为预制1;将香精加入PEG-40氢化蓖麻油搅拌溶解至透明,记为预制品2;将对羟基苯乙酮加入适量的丁二醇中,升温至60-70℃,搅拌溶解至透明,记为预制品3;将三乙醇胺与适量水混合,记为预制品4;将烟酰胺与适量水搅拌溶解至透明,记为预制品5;
3)将剩余的水加入乳化锅,将增稠剂缓慢撒水面上,浸泡5~8min,开搅拌器,在30~35Hz,搅拌2~4min,再加入甘油、剩余的丁二醇、尿囊素、预制1,升温至85~90℃,保温搅拌15~20min后,加入双-PEG-15甲基醚聚二甲基硅氧烷、乳化增稠剂,保持真空度-0.04~-0.08MPa,3000r/min内均质15min,调搅拌至35~40Hz,开冷水降温;
4)降温至45~50℃,加入舒敏植物组合物、1,2-己二醇、美白发酵产物组合物、预制品2、预制品3、预制品4、预制5,保持真空-0.04~-0.08MPa,搅拌10~15min,降温后取样检测,合格后出料。
效果验证
为了证明本发明的提供的温和防痘祛痘精华液的效果,取实施例3中组1~9的精华液用于进行DPPH自由基清除率、ABTS自由基清除率、酪氨酸酶活性抑制实验、消费者舒敏效果评价:
具体测试方法与结果:
1、DPPH自由基清除率:将一定量的料体与适量DPPH溶液混合,在黑暗中放置30min,测定517nm处的吸光值,对照空白对照组,计算清除自由基的活性,以自由基清除率(%)表示,测试结果如表3所示。
2、ABTS自由基清除率:按体积比1∶1将7mM的ABTS水溶液和2.45mM过硫酸钾溶液混合摇匀,室温避光放置16h,用无水乙醇稀释至波长734nm处的吸光值小于0.7,作为ABTS测定溶液;取一定量的测试料体,加入ABTS测定溶液,静置5min,于734nm处测定吸光度,计算清除自由基的活性,以自由基清除率(%)表示,测试结果如表3所示。
3、酪氨酸酶活性抑制实验:
采用酪氨酸酶多巴速率氧化法。各反应体系的物质加入量及顺序见表3。在加入酪氨酸酶后,将反应体系置于37℃水浴中保温10min,再加入0.98g/L的L-多巴溶液,混匀,反应3min后于475nm处测定吸光值。其中,磷酸盐缓冲液为pH=6.8,25mmol/L,计算公式如下:
式中:
A——对照组于有酪氨酸酶体系反应3min时的吸光度值;
B——对照组于无酪氨酸酶体系反应3min时的吸光度值;
C——样品组于有酪氨酸酶体系反应3min时的吸光度值;
D——样品组于无酪氨酸酶体系反应3min时的吸光度值;
I——酪氨酸酶活性抑制率%。
酪氨酸酶活性抑制率测试结果见表3。
表2反应液组成
组别 | 磷酸盐缓冲液(mL) | 待测样品(mL) | 酪氨酸酶(mL) | L-多巴(mL) |
A | 3.3 | 0.0 | 0.3 | 0.4 |
B | 3.6 | 0.0 | 0.0 | 0.4 |
C | 2.6 | 0.7 | 0.3 | 0.4 |
D | 2.9 | 0.7 | 0.0 | 0.4 |
表3 DPPH、ABTS自由基清除率和酪氨酸酶活性抑制率(I)测试结果
结果显示,组1~9的组合物皆具有抗氧化以及抑制酪氨酸酶的活性,其中:
组4的抗氧化效果不良,主要是由于其中不含有本发明所述的美白发酵产物组分,虽然其中烟酰胺的用量增加以替代美白发酵产物组分以保证抑制酪氨酸酶活性没有降低,但却导致抗氧化效果下降。
相对于其他各组,组2、组8~9在抗氧化效果方面也存在下降,其中,组2表现在对DPPH、ABTS自由基的清除率都有所下降,说明组2中,组合物中各组分的配比不及组1和组3合理,致使抗氧化效果下降。而组8的组合物中,美白发酵产物组分中缺少两个组分,致使其对ABTS自由基的清除效果下降,说明美白发酵产物组分中各组分都必不可少。而组9虽然对DPPH表现出了较高的清除效果,但因缺少舒敏组分,其对ABTS自由基的清除效果下降。这说明在本发明提供的组合物中,不仅各组分缺一不可,美白发酵产物组分中的组成对抗氧化、降低酪氨酸活性也存在重要的影响。
在组合物5~7对酪氨酸酶的抑制作用低于其他各组,说明烟酰胺或九肽-1与美白发酵产物组分相互配合能够提高抑制酪氨酸酶的效果,在同等用量下,同时含有烟酰胺与九肽-1和美白发酵产物组分的实验组抑制酪氨酸酶的活性更强。
4、消费者舒敏效果评价方法:
选择年龄在16~32岁受试者,测试人数为270人,受试者面部皮肤特征为均有不同程度的过敏症状,如红肿、瘙痒、脱皮、干燥,且均符合受试者志愿入选标准。随机分为9组,每组30人,分别对组1~9的精华液进行测试,每日早晚各1次(具体使用情况见表2所示),14天后,评估精华液的舒敏效果(主要是红肿、瘙痒、脱皮、干燥减弱情况为主要体现)。
所述有效的标准为面部过敏症状得到改善或者明显改善。
表4消费者舒敏效果评价结果
如表4所示,各组消费者使用组合物后皆反应存在一定的舒敏效果,但其中组4的舒敏效果不佳,这是由于其中以烟酰胺作为主要的美白发酵产物组分,但过量的烟酰胺对皮肤产生了刺激性。组9的舒缓作用也不佳,因其不含有舒敏组分,说明本发明所述的舒敏组分对于样品的舒敏效果存在良好的促进作用。相对于其他各组而言,组1具有更好的舒敏效果,同时其抗氧化和抑制酪氨酸酶的效果最佳,说明组1组分、配比更合理。
以上仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种组合物,其特征在于,包括:保湿剂、烟酰胺、舒敏组分,九肽-1,美白发酵产物组分;
所述保湿剂包括丁二醇、甘油、透明质酸钠和尿囊素;
所述美白发酵产物组分包括二裂酵母发酵产物溶胞物、酵母发酵产物提取物、覆膜酵母菌发酵产物滤液和乳酸杆菌发酵产物;
所述的舒敏组分包括积雪草提取物、虎杖根提取物、黄芩根提取物、马齿苋提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、玉兰花提取物和雪莲花提取物。
2.根据权利要求1所述的组合物,其特征在于,所述保湿剂中丁二醇、甘油、透明质酸钠和尿囊素的质量比为:(3~7)∶(4~8)∶(0.03~0.1)∶(0.1~0.4)。
3.根据权利要求1所述的组合物,其特征在于,所述美白发酵产物组分中,二裂酵母发酵产物溶胞物、酵母发酵产物提取物、覆膜酵母菌发酵产物滤液和乳酸杆菌发酵产物的质量比为5∶1∶2∶2。
4.根据权利要求1所述的组合物,其特征在于,所述舒敏组分中,积雪草提取物、虎杖根提取物、黄芩根提取物、马齿苋提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、玉兰花提取物、雪莲花提取物的质量比为1∶1∶1∶1∶1∶1∶1∶1∶1∶1。
5.根据权利要求1~4任一项所述的组合物,其特征在于,所述保湿剂、烟酰胺、舒敏组分,九肽-1,六肽-11,美白发酵产物组分的质量比为(7.13~15.5)∶(1~3)∶(0.2~1)∶(0.03~0.1)∶(0.01~0.05)∶(4~10)。
6.权利要求1~5任一项所述的组合物在制备具有舒敏和/或美白功能的产品中的应用。
7.一种具有舒敏和/或美白功能的精华液,其特征在于,包括权利要求1~5任一项所述的组合物和基质。
8.根据权利要求7所述的精华液,其特征在于,所述基质由双-PEG-15甲基醚聚二甲基硅氧烷、增稠剂、乳化增稠剂、黄原胶、对羟基苯乙酮、1,2-己二醇、PEG-40氢化蓖麻油、香精、三乙醇胺和水;
其中,所述增稠剂为丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物;
所述乳化增稠剂由丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷、聚山梨醇酯-80、水、山梨坦油酸酯组成。
10.权利要求7~9任一项所示的精华液的制备方法,包括:
将透明质酸钠和黄原胶与丁二醇混合,记为预制品1;
将香精加入PEG-40氢化蓖麻油,记为预制品2;
将对羟基苯乙酮加入丁二醇,升温至60~70℃,搅拌溶解,记为预制品3;
将三乙醇胺与水混合,记为预制品4;
将烟酰胺溶于水,记为预制品5;
取剩余的水,将增稠剂缓慢撒水面上,浸泡5~8min后30~35Hz,搅拌2~4min,再加入甘油、剩余的丁二醇、尿囊素、预制品1,升温至85~90℃,保温搅拌15~20min后,加入双-PEG-15甲基醚聚二甲基硅氧烷、乳化增稠剂,真空度-0.04~-0.08MPa,3000r/min均质15min,然后35~40Hz搅拌;
降温至45~50℃,加入舒敏组分、1,2-己二醇、美白发酵产物组分、预制品2、预制品3、预制品4、预制品5,保持真空-0.04~-0.08MPa,搅拌10~15min,降温至室温,制得所述精华液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010249226.0A CN111374935A (zh) | 2020-03-31 | 2020-03-31 | 含多肽的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010249226.0A CN111374935A (zh) | 2020-03-31 | 2020-03-31 | 含多肽的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111374935A true CN111374935A (zh) | 2020-07-07 |
Family
ID=71220207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010249226.0A Pending CN111374935A (zh) | 2020-03-31 | 2020-03-31 | 含多肽的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111374935A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111888306A (zh) * | 2020-07-14 | 2020-11-06 | 名臣健康用品股份有限公司 | 一种祛黑头和修复酒糟鼻的精华液及其制备方法 |
CN113081888A (zh) * | 2021-03-25 | 2021-07-09 | 榆林市恒丽贸易有限公司 | 多肽修护提取液及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943462A (zh) * | 2016-06-21 | 2016-09-21 | 韶关凌化工有限公司 | 具有祛斑美白功效的中药组合物提取液、面霜及制备方法 |
CN110025549A (zh) * | 2019-04-25 | 2019-07-19 | 广州科恩生物技术有限公司 | 一种保湿修复乳液及其制备方法 |
CN110279599A (zh) * | 2019-07-10 | 2019-09-27 | 中山卡丝生物科技有限公司 | 一种美白组合物、含美白组合物的套装及其制备方法 |
CN110585076A (zh) * | 2019-09-26 | 2019-12-20 | 广州艾蓓生物科技有限公司 | 一种益生元和益生菌组合物及其制备方法和应用 |
-
2020
- 2020-03-31 CN CN202010249226.0A patent/CN111374935A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943462A (zh) * | 2016-06-21 | 2016-09-21 | 韶关凌化工有限公司 | 具有祛斑美白功效的中药组合物提取液、面霜及制备方法 |
CN110025549A (zh) * | 2019-04-25 | 2019-07-19 | 广州科恩生物技术有限公司 | 一种保湿修复乳液及其制备方法 |
CN110279599A (zh) * | 2019-07-10 | 2019-09-27 | 中山卡丝生物科技有限公司 | 一种美白组合物、含美白组合物的套装及其制备方法 |
CN110585076A (zh) * | 2019-09-26 | 2019-12-20 | 广州艾蓓生物科技有限公司 | 一种益生元和益生菌组合物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
广州赛莱拉生物基因工程有限公司: "《赛斯兰黛水漾焕能安瓶精华液》", 《HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20200218085539B7246&NID=20200218085539B7246》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111888306A (zh) * | 2020-07-14 | 2020-11-06 | 名臣健康用品股份有限公司 | 一种祛黑头和修复酒糟鼻的精华液及其制备方法 |
CN113081888A (zh) * | 2021-03-25 | 2021-07-09 | 榆林市恒丽贸易有限公司 | 多肽修护提取液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109453087B (zh) | 美白透肌水及其制备方法和美白化妆品添加剂 | |
CN104958247A (zh) | 一种含有葛仙米提取物的身体乳及其制备方法 | |
CN112494406A (zh) | 一种美白祛斑化妆品及其制备方法 | |
CN109106677B (zh) | 一种具有美白功能的组合物及其应用 | |
CN110090191B (zh) | 一种晒后修复组合物及其化妆品 | |
CN113244144B (zh) | 一种提亮肤色的面霜 | |
CN112043661B (zh) | 一种美白芦荟胶及其制备方法 | |
CN115531272B (zh) | 一种源自高山植物的抗氧化组合物及其制备方法与应用 | |
CN112891286A (zh) | 一种塑颜紧致修护霜及其制备方法 | |
CN111374935A (zh) | 含多肽的组合物及其应用 | |
CN110236981B (zh) | 一种美白植物多糖组合物及其应用 | |
CN115517999A (zh) | 一种抗衰老组合物及其在美容护肤中的应用 | |
CN111956573A (zh) | 一种婴儿水分霜及其制备方法 | |
KR101474340B1 (ko) | 생약 발효 추출물을 포함하는 피부 노화 방지 화장료조성물 | |
CN113693991A (zh) | 一种用于有效缓解皱纹产生的组合物及其制备方法与用途 | |
CN112516025A (zh) | 一种具有透皮吸收功效的植物提取组合物乳霜及其制备方法 | |
KR20190063549A (ko) | 대나무 발효물을 함유하는 화장료 조성물 | |
CN110974775A (zh) | 一种含葛仙米的舒敏组合物及其制备方法和应用 | |
CN110664700B (zh) | 组合物及其在制备防治痤疮的产品中的应用 | |
CN115137675A (zh) | 一种具有保湿功效的复方植物提取物及应用 | |
CN115487131A (zh) | 一种日用面部皮肤护肤组合物及其制备方法 | |
CN115252497A (zh) | 一种精华液及其制备方法 | |
CN105534850B (zh) | 一种婴儿用的含蜂胶的润肤产品及其制备方法 | |
CN114533613A (zh) | 一种美白化妆品组合物及其制备方法和应用 | |
CN113440470A (zh) | 一种有效缓解熬夜皮肤不适感的组合物其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200707 |